Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. NXGL
NXGL logo

NXGL Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.095
Open
1.070
VWAP
0.92
Vol
7.01M
Mkt Cap
9.20M
Low
0.703
Amount
6.42M
EV/EBITDA(TTM)
--
Total Shares
8.14M
EV
9.59M
EV/OCF(TTM)
--
P/S(TTM)
0.74
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises CG Converting and Packaging, LLC (CGN), a joint venture with C.G. Laboratories Inc. (CG Labs) used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George.
Show More

Events Timeline

(ET)
2026-03-10
08:50:00
NexGel Signs Agreement to Acquire Celularity's Regenerative Biomaterials
select
2026-02-10 (ET)
2026-02-10
09:10:00
NEXGEL Announces $1.797M Financing for Potential Acquisition
select
2025-12-16 (ET)
2025-12-16
08:10:00
NEXGEL Announces Strategic Investment in NexGelRx
select
2025-12-11 (ET)
2025-12-11
08:20:00
NEXGEL Spins Off Drug Delivery Assets into NexGelRx
select
2025-08-05 (ET)
2025-08-05
08:21:00
NexGel appoints Steve Ciardiello to board of directors
select
2025-08-01 (ET)
2025-08-01
08:04:49
NexGel prices 413,044 shares at $2.30 in registered direct offering
select
2025-07-14 (ET)
2025-07-14
09:03:46
NexGel, STADA announce expansion of partnership for North America
select
2024-11-11 (ET)
2024-11-11
16:40:53
NexGel announces $2M registered direct offering
select
2024-10-10 (ET)
2024-10-10
09:02:13
NexGel expects Q3 revenue approx $2.85M
select
2024-10-04 (ET)
2024-10-04
09:04:44
NexGel appoints Kip Crecca to Scientific Advisory Board
select

News

Benzinga
8.5
13:02 PMBenzinga
NexGel Expects Revenue to Triple
  • Milestone Transaction: NexGel's recent transaction is regarded as a significant milestone in its history, with expected annual revenue reaching approximately $35 million by 2026, nearly tripling current figures, thus enabling immediate profitability and enhancing its position in the medical technology sector.
  • Expanded Product Portfolio: The deal adds six commercially viable regenerative biomaterial products with proven clinical utility, which not only meet market demand but also have insurance reimbursement coverage, thereby supporting a stable revenue base.
  • Future Growth Pipeline: NexGel plans to file three additional 510(k) applications in 2026, 2027, and 2028, providing a visible growth pipeline for its portfolio and further strengthening its competitive edge in the market.
  • Financing and Strategic Investments: The company anticipates closing approximately $14.9 million in financing during the first or early second quarter of 2026, alongside a previously announced financing of about $1.8 million, indicating a proactive approach to acquisitions and enhancing its market expansion capabilities.
moomoo
8.5
12:45 PMmoomoo
NEXGEL INC ANTICIPATES COMPLETING $14.9 MILLION IN EXTRA FINANCING BY Q1 OR EARLY Q2 2026
  • Funding Expectations: NEXGEL anticipates closing an additional financing round of $14.9 million in the first quarter or early second quarter of 2026.

  • Financial Strategy: The company is actively seeking to secure funds to support its growth and operational needs.

Benzinga
9.5
09:03 AMBenzinga
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
  • Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
  • Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
  • Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
  • Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
Newsfilter
8.5
02-10Newsfilter
NEXGEL Secures $1.797 Million Financing for Potential Acquisition
  • Financing Amount: NEXGEL announced a financing of $1.797 million for a potential acquisition expected to close in Q1 2026, with funds to be returned to the investor if the transaction does not proceed, indicating the company's proactive approach to mergers and acquisitions.
  • Follow-On Investment Potential: The financing may also attract an additional investment of $14.869 million, contingent on the completion of due diligence, which would further enhance the company's acquisition capabilities and market competitiveness.
  • CEO Statement: NEXGEL's CEO Adam Levy stated that after successfully integrating several acquisitions in recent years, the company continues to evaluate other accretive transactions, demonstrating its strategic commitment to business expansion.
  • Market Positioning: As a leading provider of healthcare and beauty products, NEXGEL's ultra-gentle, high-water-content hydrogel products hold a unique advantage in the market, and future acquisitions will help solidify its market position.
Newsfilter
7.5
2025-12-16Newsfilter
NEXGEL's NexGelRx Secures Investment and Strategic Advisor Appointment
  • Strategic Investment: NexGelRx has secured an undisclosed investment from Diesis Holdings, which is expected to enhance its competitive position in the drug delivery sector and drive the development and commercialization of new products.
  • Advisor Appointment: Eric Gruntfest has been appointed as a board observer and advisor for NexGelRx, bringing extensive experience in healthcare commercialization and patient access, which will provide new perspectives to the company's strategic development.
  • Product Potential: NexGelRx's ultra-gentle hydrogel products are viewed as ideal transdermal delivery mechanisms, anticipated to offer innovative delivery solutions for a wide range of pharmaceuticals, thereby increasing market appeal.
  • Market Positioning: With over 20 years of experience in healthcare and consumer products, combined with the new investment and advisor's expertise, NEXGEL is expected to further solidify its leadership position in the health and beauty product market.
NASDAQ.COM
9.5
2025-08-13NASDAQ.COM
Nexgel Revenue Jumps 100% in Fiscal Q2
  • Financial Performance: Nexgel reported a 100.3% year-over-year increase in GAAP revenue to $2.88 million for Q2 2025, although it fell short of analyst expectations by 6.5%. The company also improved its gross margin significantly to 43.6%, but continued to face net losses and high operating expenses.

  • Growth Strategy: The company is focusing on expanding its branded product offerings and contract manufacturing partnerships, including a notable collaboration with STADA. Management maintains a full-year revenue target of $13 million and anticipates stronger performance in the second half of the year through new product launches and customer acquisitions.

Valuation Metrics

The current forward P/E ratio for Nexgel Inc (NXGL.O) is -13.66, compared to its 5-year average forward P/E of -15.49. For a more detailed relative valuation and DCF analysis to assess Nexgel Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-15.49
Current PE
-13.66
Overvalued PE
5.18
Undervalued PE
-36.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
25.96
Current EV/EBITDA
329.22
Overvalued EV/EBITDA
117.69
Undervalued EV/EBITDA
-65.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.43
Current PS
0.94
Overvalued PS
3.81
Undervalued PS
1.06

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

inom den amerikanska marknaden
Intellectia · 15 candidates
Market Cap: <= 1.50BPrice: <= $25.00Beta: HighRiskRsi 14: <= 45Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
SG logo
SG
Sweetgreen Inc
820.33M
NVX logo
NVX
NOVONIX Ltd
222.62M
LFMD logo
LFMD
LifeMD Inc
170.40M
TMCI logo
TMCI
Treace Medical Concepts Inc
166.30M
HFFG logo
HFFG
Hf Foods Group Inc
116.17M
PYXS logo
PYXS
Pyxis Oncology Inc
103.36M

Whales Holding NXGL

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Nexgel Inc (NXGL) stock price today?

The current price of NXGL is 0.9518 USD — it has decreased -15.75

What is Nexgel Inc (NXGL)'s business?

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises CG Converting and Packaging, LLC (CGN), a joint venture with C.G. Laboratories Inc. (CG Labs) used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George.

What is the price predicton of NXGL Stock?

Wall Street analysts forecast NXGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NXGL is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Nexgel Inc (NXGL)'s revenue for the last quarter?

Nexgel Inc revenue for the last quarter amounts to 2.93M USD, decreased -0.20

What is Nexgel Inc (NXGL)'s earnings per share (EPS) for the last quarter?

Nexgel Inc. EPS for the last quarter amounts to -0.08 USD, decreased -27.27

How many employees does Nexgel Inc (NXGL). have?

Nexgel Inc (NXGL) has 19 emplpoyees as of March 10 2026.

What is Nexgel Inc (NXGL) market cap?

Today NXGL has the market capitalization of 9.20M USD.